drugset / Trial / NCT00003405
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.
Timeline
- Start
- 1998-04
- Primary completion
- 1999-04
- Completion
- 1999-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Idarubicin | Small molecule | — | Intravenous |
| Subject | Isotretinoin | Other / unclassified | — | Oral |
| Subject | Mitoxantrone | Small molecule | — | Intravenous |
| Subject | amifostine | Unknown | — | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |
| Background | bromodeoxyuridine | Unknown | — | Intravenous |
| Background | idoxuridine | Small molecule | — | Intravenous |